Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated in January 2020 and, on March, the WHO declared the status of a pandemic. It causes a cytokine release syndrome, called “cytokine storm,” characterized by systemic inflammation involving elevated levels of cytokines and hypera...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Infante Barbara, Mercuri Silvia, Troise Dario, Castellano Giuseppe, Giovanni Stallone
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	COVID-19 tocilizumab graft dysfunction acute kidney injury transplantation Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b057a0dfb3ee449f8acb1c627e17313a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b057a0dfb3ee449f8acb1c627e17313a
record_format	dspace
spelling	oai:doaj.org-article:b057a0dfb3ee449f8acb1c627e17313a2021-12-01T01:15:10ZCase Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-192296-858X10.3389/fmed.2021.732792https://doaj.org/article/b057a0dfb3ee449f8acb1c627e17313a2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.732792/fullhttps://doaj.org/toc/2296-858XSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated in January 2020 and, on March, the WHO declared the status of a pandemic. It causes a cytokine release syndrome, called “cytokine storm,” characterized by systemic inflammation involving elevated levels of cytokines and hyperactivation of immune cell; this profound alteration in the immune system led to an overshooting inflammatory response contributing to morbidity and mortality. Solid organ transplant recipients are at particularly higher risk of developing critical coronavirus disease 2019 (COVID-19) due to chronic immunosuppression; in fact, establishing the balance between infection and rejection in any transplant recipient is the principal aim when prescribing immunosuppression. Tocilizumab, a humanized monoclonal antibody against interleukin-6 (IL-6) receptor widely adopted in adult rheumatoid arthritis, is used as rescue therapy for chronic antibody-mediated rejection in kidney transplantation. Data about the use of tocilizumab for treating acute kidney graft dysfunction in a setting of kidney-transplanted patients affected by COVID-19 are lacking. In this case study, we discuss the case of kidney transplant recipient with proven SARS-CoV-2 infection that develops acute graft dysfunction and the management of immunosuppression with concomitant tocilizumab administration.Infante BarbaraMercuri SilviaTroise DarioCastellano GiuseppeCastellano GiuseppeCastellano GiuseppeGiovanni StalloneFrontiers Media S.A.articleCOVID-19tocilizumabgraft dysfunctionacute kidney injurytransplantationMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 tocilizumab graft dysfunction acute kidney injury transplantation Medicine (General) R5-920
spellingShingle	COVID-19 tocilizumab graft dysfunction acute kidney injury transplantation Medicine (General) R5-920 Infante Barbara Mercuri Silvia Troise Dario Castellano Giuseppe Castellano Giuseppe Castellano Giuseppe Giovanni Stallone Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19
description	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated in January 2020 and, on March, the WHO declared the status of a pandemic. It causes a cytokine release syndrome, called “cytokine storm,” characterized by systemic inflammation involving elevated levels of cytokines and hyperactivation of immune cell; this profound alteration in the immune system led to an overshooting inflammatory response contributing to morbidity and mortality. Solid organ transplant recipients are at particularly higher risk of developing critical coronavirus disease 2019 (COVID-19) due to chronic immunosuppression; in fact, establishing the balance between infection and rejection in any transplant recipient is the principal aim when prescribing immunosuppression. Tocilizumab, a humanized monoclonal antibody against interleukin-6 (IL-6) receptor widely adopted in adult rheumatoid arthritis, is used as rescue therapy for chronic antibody-mediated rejection in kidney transplantation. Data about the use of tocilizumab for treating acute kidney graft dysfunction in a setting of kidney-transplanted patients affected by COVID-19 are lacking. In this case study, we discuss the case of kidney transplant recipient with proven SARS-CoV-2 infection that develops acute graft dysfunction and the management of immunosuppression with concomitant tocilizumab administration.
format	article
author	Infante Barbara Mercuri Silvia Troise Dario Castellano Giuseppe Castellano Giuseppe Castellano Giuseppe Giovanni Stallone
author_facet	Infante Barbara Mercuri Silvia Troise Dario Castellano Giuseppe Castellano Giuseppe Castellano Giuseppe Giovanni Stallone
author_sort	Infante Barbara
title	Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19
title_short	Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19
title_full	Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19
title_fullStr	Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19
title_full_unstemmed	Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19
title_sort	case report: tocilizumab for acute kidney graft dysfunction in patient affected by covid-19
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/b057a0dfb3ee449f8acb1c627e17313a
work_keys_str_mv	AT infantebarbara casereporttocilizumabforacutekidneygraftdysfunctioninpatientaffectedbycovid19 AT mercurisilvia casereporttocilizumabforacutekidneygraftdysfunctioninpatientaffectedbycovid19 AT troisedario casereporttocilizumabforacutekidneygraftdysfunctioninpatientaffectedbycovid19 AT castellanogiuseppe casereporttocilizumabforacutekidneygraftdysfunctioninpatientaffectedbycovid19 AT castellanogiuseppe casereporttocilizumabforacutekidneygraftdysfunctioninpatientaffectedbycovid19 AT castellanogiuseppe casereporttocilizumabforacutekidneygraftdysfunctioninpatientaffectedbycovid19 AT giovannistallone casereporttocilizumabforacutekidneygraftdysfunctioninpatientaffectedbycovid19
_version_	1718406042157580288

Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19

Ejemplares similares